Articles

Journal of Endovascular Therapy Hypertension Renal Denervation Therapy

Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. 

May 14, 2014 — The Department of Health and Human Services (HHS) announced that new preliminary data show an overall 9 percent decrease in hospital-acquired conditions nationally during 2011 and...

It is impossible to escape the reality that as the use of mobile electronic devices increases amongst consumers, a proportionate increase in the use of such devices in the medical sales and...

Medtronic, SYMPLICITY, SYMPLICITY HTN-3 trial, renal denervation, ACC.14

A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial....

FDA Premarket Approval PMA Clinical Study EP Lab Cath Leads Implantable Devices

The U.S. Food and Drug Administration (FDA) has approved many cardiac implantable electronic device...

Medtronic, symplicity, renal denervation

Medtronic Inc. announced its U.S. pivotal trial for its Symplicity renal denervation system to treat resistant hypertension, the SYMPLICITY HTN-3 trial, failed to meet its primary efficacy...

medtronic symplicity spyral renal denervation cath lab hypertension treatment G3

Medtronic Inc. announced CE mark in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its flexible 4 French multi-electrode Symplicity Spyral ...

The 2014 Top 10 Health Technology Hazards list raises awareness of the potential dangers associated with the use of medical devices and helps healthcare providers minimize the risk of technology-...

CORAL trial subgroups, renal stenting

The use of renal stenting in combination with medication-based therapy to treat hypertension showed no improvement in patient outcomes over the use of medications alone in treating hypertension....

renal denervation clinical trial study hypertension cath medtronic symplicity

Medtronic Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE), allowing the company to initiate SYMPLICITY HTN-4, the first...